Date: 2015-05-26
Type of information: Collaboration agreement
Compound: CicloMulsion® (Cremophor®-free intravenous cyclosporine formulation)
Company: Neurovive Pharmaceutical (Sweden) Sanofi (France)
Therapeutic area: Cardiovascular diseases
Type agreement: development collaboration commercialisation
Action mechanism: immunosuppressive agent. The active ingredient cyclosporine acts by preventing the death of mitochondria in damaged cells and the following cascade of intracellular biochemical events that lead to secondary tissue damage. By protecting a cell\'s mitochondria, NeuroVive\'s products ensure that energy production is preserved and a damaged cell\'s normal regenerative mechanisms can act to repair and maintain the cell.
Disease: reperfusion injury in cardiovascular disease
Details: * On May 26, 2015, NeuroVive Pharmaceutical, the mitochondrial medicine company, announced that NeuroVive Pharmaceutical Asia group has signed a collaboration agreement with Sanofi’s local affiliate for the development and commercialization of CicloMulsion® in South Korea. Under the agreement NeuroVive Asia will get an upfront payment, a conditional milestone payment and royalty on potential future sales in South Korea. CicloMulsion® is being developed for the treatment of reperfusion injury in cardiovascular disease. The NeuroVive group is carrying out an extensive international program for the clinical development and commercialization of CicloMulsion® ahead of the product’s potential market launch. The collaboration agreement between NeuroVive Pharmaceutical Asia Limited, a subsidiary of NeuroVive Pharmaceutical Asia, Inc., and Sanofi’s local affiliate represents another step in this process. CicloMulsion® is currently being evaluated for the treatment of reperfusion injury following myocardial infarct in a European clinical phase III study (the CIRCUS study). The product is also being evaluated for the treatment of other acute heart and kidney injuries within the framework of the collaboration with Hospices Civils de Lyon and in a clinical phase II study in collaboration with Skåne University Hospital in Lund, Sweden.
Financial terms:
Latest news:
